Lack of agreement between the plasma lipid-based criteria and apoprotein B for the diagnosis of familial combined hyperlipidemia in members of familial combined hyperlipidemia kindreds

Metabolism: Clinical and Experimental

Volumn 51, Issue 2, 2002, Pages 218-224

  Del Rincon Jarero, Juan Pablo ^a   Aguilar Salinas, Carlos A ^a   Guillén Pineda, Luz E ^a   Goémez Pérez, Francisco J ^a   Rull, Juan A ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONSTANTS AND COEFFICIENTS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET RESTRICTION; FAMILIAL HYPERLIPEMIA; FAMILY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LINKAGE ANALYSIS; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036176025     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.29993     Document Type: Article

References (54)

1. Familial combined hyperlipidemia workshop
2. Genetics of lipoprotein disorders
3. Is familial combined hyperlipidaemia a genetic disorder of adipose tissue?
4. Hyperlipidemia in coronary heart disease. II: Genetic analysis of lipid levels in 176 families and delineation of a new inhereted disorder, combined hyperlipidemia
5. Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity
6. Mapping a gene for combined hyperlipidemia in a mutant mouse strain
7. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia
8. Defects of lipoprotein metabolism in familial combined hyperlipidaemia
9. Metabolic basis for hypertriglyceridaemia in familial combined hyperlipidaemia
10. Glucose intolerance in familial combined hyperlipidaemia. EUFAM Study Group
11. Familial combined hyperlipidemia
12. Familial combined hyperlipidemia: Use of stable isotopes to demonstrate overproduction of very low density lipoprotein apolipoprotein B by the liver
13. Metabolic basis of hyperapobetalipoproteinemia: Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia
14. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy
15. Very low density overproduction in genetic forms of hypertriglyceridemia
16. Integrated regulation of very low density lipoprotein triglycerides and apolipoprotein B kinetics in man: Normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia
17. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglycerides and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia
18. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families
19. Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia
20. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex
21. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia
22. Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia
23. Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia
24. Different regulation of free fatty acid levels and glucose oxidation by the Trp64Arg polymorphism of the beta3-adrenergic receptor gene and the promoter variant (A-3826G) of the uncoupling protein 1 gene in familial combined hyperlipidemia
25. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia
26. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia
27. Support for linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Chinese and German families
28. Mutations of the human hepatic lipase in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia
29. Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus
30. The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia
31. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes
32. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia
33. Linkage of a candidate gene locus to familial combined hyperlipidemia: Lecithin: Cholesterol acyltransferase on 16q
34. Influence of obesity on plasma lipoproteins, glycaemia and insulinaemia in patients with familial combined hyperlipidaemia
35. Plasma triglycerides and LDL heterogeneity in familial combined hyperlipidemia
36. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity
37. A study of insulin resistance using the minimal model in nondiabetic familial combined hyperlipidemic patients
38. Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease
39. Coronary flow reserve in young men with familial combined hyperlipidemia
40. Familial combined hyperlipidemia and abnormal lipoprotein lipase
41. In vivo evidence of defective postprandial and postabsortive free fatty acid metabolism in familial combined hyperlipidemia
42. Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia
43. Estimation of the concentration of low density lipoproteins cholesterol in plasma without the use of the ultracentrifuge
44. Weighted kappa: Nominal scale agreement with provision for scale disagreement or partial credit
45. The measurement of observer agreement for categorical data
46. AACE lipid guidelines
47. Summary of the second report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol (Adult treatment panel II)
48. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
49. Phenotype expression in familial combined hyperlipidemia
50. Metabolic modes of action of statins in the hyperlipoproteinemias
51. Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: A study in familial combined hyperlipidemia
52. Apolipoprotein AI and B concentrations and the risk of ischemic heart disease during a 5 year follow up of men in the Quebec cardiovascular study
53. Apolipoprotein B and AI distribution in the United States, 1988-1991: Results of the National Health and Nutrition Examination Survey III (NHANES III)
54. Genomewide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels